Friends of UTokyo, Inc.

During her time at the University of Tokyo, Dr. Delawary studied genetic engineering in the Faculty of Agriculture for her undergraduate and master’s programs. She then transitioned to the Institute of Medical Science for her doctoral program, where she conducted research in molecular biology and neuroscience, ultimately earning her PhD.

Following her PhD, Dr. Delawary joined Daiichi Sankyo, where she conducted pharmacological research for about 15 years. She also spent a few years as a postdoctoral researcher at Harvard University, focusing on stem cell biology, specifically investigating the causes of diseases related to embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells).

Three years ago, Dr. Delawary transitioned to a role as a project manager for clinical trials of anti-cancer drugs at Daiichi Sankyo. Since April 2024, she has been based at the company’s office in New Jersey, USA.